2018
A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients
Giannini C, D'ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, Velazquez EJ, Armeni P, Adamo M, De Carlo M, Petronio AS. A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. ESC Heart Failure 2018, 5: 1150-1158. PMID: 30191666, PMCID: PMC6300824, DOI: 10.1002/ehf2.12339.Peer-Reviewed Original ResearchConceptsFunctional mitral regurgitationMedical therapyMitral regurgitationSurvival benefitConservative treatmentPercutaneous mitral valve repairEffect of MitraClipRobust survival benefitSignificant survival benefitCardiac resynchronization therapyEligible observational studiesHeart failure patientsVentricular ejection fractionMitral valve repairPatient-level analysisComprehensive literature searchStudy-level analysisConservative therapyIschemic etiologyPrimary endpointFailure patientsMultivariate adjustmentEjection fractionResynchronization therapySurvival outcomes
2015
Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs
DeVore AD, Schulte PJ, Mentz RJ, Hardy NC, Kelly JP, Velazquez EJ, Maya JF, Kielhorn A, Patel HK, Reed SD, Hernandez AF. Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. The American Journal Of Cardiology 2015, 117: 946-951. PMID: 26805662, PMCID: PMC5429586, DOI: 10.1016/j.amjcard.2015.12.031.Peer-Reviewed Original ResearchConceptsBeats/minReduced ejection fractionElevated heart rateHeart rateHeart failureEjection fractionΒ-blockersMedical costsHospital cost accounting dataLarge tertiary care centerMortality/hospitalizationTertiary care centerOne-year outcomesDirect medical costsNational death recordsRoutine clinical practiceMedian heart rateProportional hazards modelDuke University HospitalHeart rate assessmentElectronic medical recordsCause mortalityEligible patientsMultivariate adjustmentAtrial fibrillation
2013
Early Echocardiographic Deformation Analysis for the Prediction of Sudden Cardiac Death and Life-Threatening Arrhythmias After Myocardial Infarction
Ersbøll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, Møller JE, Kisslo J, Velazquez EJ, Hassager C, Søgaard P, Køber L. Early Echocardiographic Deformation Analysis for the Prediction of Sudden Cardiac Death and Life-Threatening Arrhythmias After Myocardial Infarction. JACC Cardiovascular Imaging 2013, 6: 851-860. PMID: 23850252, DOI: 10.1016/j.jcmg.2013.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAgedArrhythmias, CardiacDeath, Sudden, CardiacDefibrillators, ImplantableDenmarkEchocardiographyElectric CountershockFemaleHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrimary PreventionProportional Hazards ModelsProspective StudiesRisk FactorsStroke VolumeTreatment OutcomeVentricular Function, LeftConceptsGlobal longitudinal strainAcute myocardial infarctionSudden cardiac deathMalignant ventricular arrhythmiasMyocardial infarctionNet reclassification indexVentricular arrhythmiasCardiac deathAddition of GLSMeasurement of GLSSCD/VAsChronic ischemic heart failureNovel echocardiographic parametersPrimary composite endpointPrimary composite outcomeIschemic heart failureEchocardiographic parametersPrimary endpointComposite outcomeHospital dischargeLate complicationsMultivariate adjustmentComposite endpointHeart failureRisk stratification
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2008
Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention
Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of Left Ventricular Dysfunction on Hospital Mortality Among Patients Undergoing Elective Percutaneous Coronary Intervention. The American Journal Of Cardiology 2008, 103: 355-360. PMID: 19166689, DOI: 10.1016/j.amjcard.2008.09.088.Peer-Reviewed Original ResearchConceptsElective percutaneous coronary interventionPercutaneous coronary interventionHospital mortalityEjection fractionCoronary interventionOdds ratioLeft ventricular systolic dysfunctionHospital mortality increasesReduced ejection fractionRetrospective cohort studyVentricular systolic dysfunctionLeft ventricular dysfunctionLow ejection fractionLV ejection fractionAdjusted hospital mortalitySystolic dysfunctionVentricular dysfunctionCohort studyMultivariate adjustmentMedical therapyEF groupPatientsMortalityOutcome variablesMortality increases